サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439939

HPV検査・パップテスト - 世界市場の考察、競合情勢、市場予測（2030年）

HPV Testing and Pap Test - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
HPV検査・パップテスト - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のHPV検査・パップテストの市場規模は、2023年に33億米ドルと評価され、2030年までに47億2,000万米ドルに達し、2024年～2030年の予測期間にCAGRで6.17％の成長が見込まれます。市場は、世界中での子宮頸がん有病率の上昇やスクリーニングプログラムの増加などの要因により、活況を示す見込みです。HPV検査・パップテストに対する認知の向上も、予測期間（2024年～2030年）におけるHPV検査・パップテスト市場の収益成長をもたらす要因の1つです。

HPV検査・パップテストの市場力学

HPV検査・パップテスト市場の主な促進要因の1つは、子宮頸がんの有病率の上昇です。子宮頸がんは、膣につながる子宮の下部である子宮頸部の細胞に発生するがんの一種です。子宮頸がん患者の増加により、事前のスクリーニングと検査に対する意識が高まり、HPV検査・パップテスト市場の成長につながっています。

WHOが2022年に発表したデータによると、子宮頸がんは世界中の女性で4番目に多いがんであり、2020年に新たに60万4,000人が発症し、34万2,000人が死亡すると推定されています。2020年の世界の新規症例と死亡者の約90％は低中所得国で発生しています。

このように、生殖年齢の女性における子宮頸がんの有病率の増加は、HPV検査・パップテストに対する需要を増大させており、2024年～2030年の予測期間に市場成長を押し上げると見込まれます。

さらに、政府機関による子宮頸がんに対する認識を高める取り組みの増加は、HPVスクリーニングの市場をさらに拡大させ、HPV検査・パップテストの市場成長を促進しています。

例えば、2020年のWorld Health Assemblyは、公衆衛生問題としての子宮頸がんの撲滅を加速するグローバル戦略を採択しました。子宮頸がん撲滅の定義は、女性10万人当たりの子宮頸がん罹患数が年間4人未満というしきい値に達する国として設定されています。21世紀末までにこのしきい値に到達するために、WHOは2030年までに、35歳までに70％の女性を高性能検査でスクリーニングし、45歳までに再びスクリーニングするという目標を設定しています。このように、2024年～2030年の予測期間におけるHPV検査・パップテスト市場の成長を促進しています。

さらに、HPVのスクリーニングに向けた製品開発の進歩は、HPV検査・パップテスト市場の成長における有利な成長機会につながっています。Qiagenのような企業は、子宮頸部サンプル中の13の高リスクなHPVタイプの存在を検出するCapture 2検査のようなHPV DNAを検出する先進技術を利用した検査を行っています。

COVID-19はHPV検査・パップテスト市場に悪影響を及ぼしています。COVID-19の規制により、多くの国がロックダウンされ、さまざまな疾患の診断を含む医療サービスの低下につながっています。2020年、世界中でCOVID-19パンデミックが高まる中、その他の緊急のニーズを優先し、COVID-19の拡大のリスクを減らすために、がんスクリーニングを含むさまざまな選択的医療処置の多くが延期されていることが判明しました。このため、がんスクリーニングの大幅な減少が見られ、HPV検査・パップテスト市場の収益成長に影響を及ぼしています。

さらに、子宮頸がんを確実に減少させるための、ウイルスに対するHPVワクチンの発売は、HPV検査・パップテスト市場の成長抑制要因の1つであり、2024年～2030年の予測期間中の市場成長に影響を与える見込みです。

HPV検査・パップテスト市場のセグメント分析

HPV検査・パップテスト市場の用途セグメントでは、子宮頸がんが2023年に最大の市場シェアを占めました。これは、近年の子宮頸がんスクリーニング検査の増加によるものと考えられます。

当レポートでは、世界のHPV検査・パップテスト市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 HPV検査・パップテスト市場レポートのイントロダクション

第2章 HPV検査・パップテスト市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 HPV検査・パップテスト市場の主な要因の分析

  • HPV検査・パップテスト市場の促進要因
  • HPV検査・パップテスト市場の抑制要因と課題
  • HPV検査・パップテスト市場の機会

第4章 HPV検査・パップテスト市場のポーターのファイブフォース分析

第5章 HPV検査・パップテスト市場に対するCOVID-19の影響分析

第6章 HPV検査・パップテスト市場のレイアウト

  • 検査タイプ別
    • 一次HPV検査
    • ガラス併用検査
    • パップテスト
  • 用途別
    • 子宮頸がん
    • 膣がん
    • その他
  • 技術タイプ別
    • ポリメラーゼ連鎖反応
  • エンドユーザー別
    • 病院、診療所
    • 診断検査室
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第7章 HPV検査・パップテスト市場の企業と製品のプロファイル

  • Arbor Vita Corporation
  • Danaher Corporation (Cepheid)
  • Seegene Inc.
  • Becton, Dickinson and Company
  • TruScreen
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • OncoHealth Corporation
  • Takara Bio Inc.
  • Promega Corporation
  • Quest Diagnostics
  • Femasys Inc.
  • Mylab Discovery Solutions Pvt Ltd.
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • Nurx

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Table 3: HPV testing and pap test market in Global (2021-2030)
  • Table 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Table 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Table 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Table 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Table 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Table 9: HPV testing and pap test market in North America (2021-2030)
  • Table 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Table 11: HPV testing and pap test market in the US (2021-2030)
  • Table 12: HPV testing and pap test market in Canada (2021-2030)
  • Table 13: HPV testing and pap test market in Mexico (2021-2030)
  • Table 14: HPV testing and pap test market in Europe (2021-2030)
  • Table 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Table 16: HPV testing and pap test market in France (2021-2030)
  • Table 17: HPV testing and pap test market in Germany (2021-2030)
  • Table 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Table 19: HPV testing and pap test market in Italy (2021-2030)
  • Table 20: HPV testing and pap test market in Spain (2021-2030)
  • Table 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Table 22: HPV testing and pap test market in APAC (2021-2030)
  • Table 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Table 24: HPV testing and pap test market in China (2021-2030)
  • Table 25: HPV testing and pap test market in Japan (2021-2030)
  • Table 26: HPV testing and pap test market in India (2021-2030)
  • Table 27: HPV testing and pap test market in Australia (2021-2030)
  • Table 28: HPV testing and pap test market in South Korea (2021-2030)
  • Table 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Table 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Table 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Table 32: HPV testing and pap test market in Middle East (2021-2030)
  • Table 33: HPV testing and pap test market in Africa (2021-2030)
  • Table 34: HPV testing and pap test market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Figure 3: HPV testing and pap test market in Global (2021-2030)
  • Figure 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Figure 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Figure 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Figure 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Figure 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Figure 9: HPV testing and pap test market in North America (2021-2030)
  • Figure 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Figure 11: HPV testing and pap test market in the US (2021-2030)
  • Figure 12: HPV testing and pap test market in Canada (2021-2030)
  • Figure 13: HPV testing and pap test market in Mexico (2021-2030)
  • Figure 14: HPV testing and pap test market in Europe (2021-2030)
  • Figure 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Figure 16: HPV testing and pap test market in France (2021-2030)
  • Figure 17: HPV testing and pap test market in Germany (2021-2030)
  • Figure 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Figure 19: HPV testing and pap test market in Italy (2021-2030)
  • Figure 20: HPV testing and pap test market in Spain (2021-2030)
  • Figure 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Figure 22: HPV testing and pap test market in APAC (2021-2030)
  • Figure 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Figure 24: HPV testing and pap test market in China (2021-2030)
  • Figure 25: HPV testing and pap test market in Japan (2021-2030)
  • Figure 26: HPV testing and pap test market in India (2021-2030)
  • Figure 27: HPV testing and pap test market in Australia (2021-2030)
  • Figure 28: HPV testing and pap test market in South Korea (2021-2030)
  • Figure 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Figure 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Figure 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Figure 32: HPV testing and pap test market in Middle East (2021-2030)
  • Figure 33: HPV testing and pap test market in Africa (2021-2030)
  • Figure 34: HPV testing and pap test market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0620

HPV Testing And PAP Test Market By Test Type (Primary HPV Testing, Co-Testing, And Pap Test), By Application (Cervical Cancer, Vaginal Cancer, And Others), By Technology Type (Polymerase Chain Reaction, And Others), By End-User (Hospitals And Clinics, Diagnostic Laboratories, And Others) by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to rising prevalence of cervical cancer and increased awareness

The global HPV testing and Pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030. The HPV testing and Pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

HPV Testing And PAP Test Market Dynamics:

One of the major factors which are driving the HPV testing and pap test market is the rising prevalence of cervical cancer. Cervical cancer is a type of cancer that occurs in the cells of the cervix which is the lower part of the uterus that connects to the vagina. The increase in the rate of cervical cases has created an awareness for prior screening and testing which has led to a growth in the HPV testing and pap test market.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries.

Thus, the increasing prevalence of cervical cancer among women of reproductive age is increasing the demand for HPV testing and pap test, which is anticipated to boost the market's growth over the forecast period from 2024-2030.

Moreover, increasing initiatives by government bodies to create awareness for cervical cancer has further increased the market for HPV screening thereby fueling the market growth for HPV testing and pap test.

For instance, the World Health Assembly in 2020 adopted the global strategy to accelerate the elimination of cervical cancer as a public health problem. The definition of elimination of cervical cancer has been set up as a country reaching the threshold of fewer than 4 cases of cervical cancer per 100,000 women per year. To reach this threshold by the end of the 21st century, WHO has set up a target to be reached by 2030 by screening 70% of women with a high-performance test by 35, and again by 45 years of age. Thus, driving the growth of the HPV testing and pap test market in the forecast period of 2024-2030.

Furthermore, advancement in product development for the screening of HPV has led to lucrative growth opportunities in the HPV testing and pap test market growth. Companies like Qiagen are having technologically advanced tests that detect HPV DNA such as the Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample.

COVID-19 has adversely impacted the HPV testing and pap test market. Due to COVID-19 restrictions, many countries were in lockdown leading to a decline in healthcare services, including the diagnosis of various diseases. In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening, thereby affecting the revenue growth of the HPV testing and pap test market.

Furthermore, the launch of the HPV vaccine against the virus to ensure the decline in cervical cancer is one of the restraining factors to the growth of the HPV testing and pap test market that will impact the market growth during the forecast period from 2024-2030.

HPV Testing And PAP Test Market Segment Analysis:

HPV testing and Pap test market by Test Type (Primary HPV Testing, Co-Testing, and Pap Test), by Application (Cervical Cancer, Vaginal Cancer, and Others), by Technology Type (Polymerase Chain Reaction, and Others), by End-User (Hospitals And Clinics, Diagnostic Laboratories, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the application segment of the HPV testing and pap test market, cervical cancer accounted for the largest market share in the year 2023. This can be ascribed to the increase in cervical cancer screening tests lately.

Cervical cancer screening is an essential part of a woman's routine healthcare. For women of age 30 years and above, an HPV test is recommended for detection. Almost 95% of cervical cancer causes the causative organisms estimated to be the HP virus. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. Therefore, the WHO in 2020 adopted the Global strategy towards eliminating cervical cancer as a public health problem and recommends a comprehensive approach to cervical cancer prevention and control.

Furthermore, in September 2018, the Ministers of Health of the Americas, at the Pan American Health Organization initiated an "Its Time to End Cervical Cancer" campaign to reduce cervical cancer by 2030. To accomplish this, the plan aims to strengthen primary prevention through information and education and HPV vaccination, as well as improve cervical cancer screening and treatment of precancerous lesions, and strengthen access to cancer diagnosis, treatment, rehabilitation, and palliative care.

All these increases in cervical cancer numbers and subsequent awareness programs for the same correspond to the increased market share of the segment, thereby increasing the market growth for the HPV testing and pap test market.

North America is expected to dominate the overall HPV Testing And PAP Test Market:

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

As per CDC 2022 data, each year in the US, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Hispanic women have the highest rates of developing cervical cancer, and Black women have the highest rates of dying from cervical cancer. Therefore, such numbers indicate considerable market growth in this region.

Therefore, with the rising cases of cervical cancer in the region, the government has adopted various awareness programs to decrease the incidence rate of the disease. A few of them are the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening, the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening. This is one of the major factors expected to drive the North American market for HPV testing and Pap test during the forecast period.

Apart from this, various research and development activities in the North American region for the HPV testing and pap test market are also key factors for the dominance in the market share.

For instance, in 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours.

Therefore, the above-mentioned factors are expected to bolster the growth of the HPV testing and pap test market in the North American region during the forecast period of 2024-2030.

HPV Testing And PAP Test Market Key Players:

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

Recent Developmental Activities In The HPV Testing And PAP Test Market:

In September 2022, Diagnostics player Mylab Discovery Solutions announced the launch of the 'PathoDetect HPV Detection Test', a real-time PCR-based screening solution to detect high-risk types of human papillomaviruses in individuals.

In June 2022, Roche announced the launch of an HPV self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analyzed with the Roche Cobas HPV test on a Roche molecular instrument.

Key Takeaways from the HPV Testing And PAP Test Market Report Study

  • Market size analysis for current HPV testing and pap test market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the HPV testing and pap test market.
  • Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
  • Key companies dominating the global HPV testing and pap test market.
  • Various opportunities available for the other competitor in the HPV testing and pap test market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current HPV testing and pap test market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for HPV testing and pap test market growth in the coming future?

Target Audience who can be benefited from this HPV Testing And PAP Test Market Report Study

  • HPV testing and pap test products providers
  • Research organizations and consulting companies
  • HPV testing and pap test -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in HPV testing and pap test
  • Various distribution channels who want to know more about the HPV testing and pap test market and the latest product innovations in the HPV testing and pap test market.

Frequently Asked Questions for HPV Testing and The PAP Test Market:

1. What are HPV testing and pap test?

The HPV test looks for the virus (human papillomavirus) that can cause cell changes on the cervix causing cervical cancer. Whereas, the Pap test (or Pap smear) looks for precancers and cell changes on the cervix that might become cervical cancer if they are not treated appropriately. These tests include microscopic observation of specimens.

2. What is the market for global HPV testing and pap test?

The global HPV testing and pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030.

3. What are the drivers for the global HPV testing and pap test market?

The HPV testing and pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

4. Who are the key players operating in the global HPV testing and pap test market?

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

5. Which region has the highest share in the HPV testing and pap test market?

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

Table of Contents

1. HPV testing and pap test market Report Introduction

2. HPV testing and pap test market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. HPV testing and pap test market Key Factors Analysis

  • 3.1. HPV testing and pap test market Drivers
    • 3.1.1. Rising prevalence of cervical cancer
    • 3.1.2. Increase in awareness
    • 3.1.3. Increase in the number of screening programs
  • 3.2. HPV testing and pap test market Restraints and Challenges
    • 3.2.1. Launch of vaccine for cervical cancer prevention
  • 3.3. HPV testing and pap test market Opportunities
    • 3.3.1. Research and development for new diagnostic technologies
    • 3.3.2. The opportunistic market for Low and Middle-Income Countries

4. HPV testing and pap test market Porter's Five Forces Analysis

  • 4.1 .Bargaining Power of Suppliers
  • 4.2 .Bargaining Power of Consumers
  • 4.3 .Threat of New Entrants
  • 4.4 .Threat of Substitutes
  • 4.5 .Competitive Rivalry

5. COVID-19 Impact Analysis on HPV testing and pap test market

6. HPV testing and pap test market Layout

  • 6.1. By Test Type
    • 6.1.1. Primary HPV Testing
    • 6.1.2. Glass Co-Testing
    • 6.1.3. Pap Test
  • 6.2. By Application
    • 6.2.1. Cervical cancer
    • 6.2.2. Vaginal cancer
    • 6.2.3. Others
  • 6.3. By Technology Type
    • 6.3.1. Polymerase chain reaction
    • 6.3.2. Others
  • 6.4. By End User
    • 6.4.1. Hospital and clinics
    • 6.4.2. Diagnostic labs
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.2. Canada HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.3. Mexico HPV testing and pap test market in USD million (2021-2030)
    • 6.5.2. Europe
      • 6.5.2.1. France HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.2. Germany HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.3. United Kingdom HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.4. Italy HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.5. Spain HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe HPV testing and pap test market in USD million (2021-2030)
    • 6.5.3. Asia-Pacific
      • 6.5.3.1. China HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.2. Japan HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.3. India HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.4. Australia HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.5. South Korea HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.6. Rest of the Asia Pacific HPV testing and pap test market in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW)
      • 6.5.4.1. Middle East HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.2. Africa HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.3. South America HPV testing and pap test market in USD million (2021-2030)

7. HPV testing and pap test market Company and Product Profiles

  • 7.1. Arbor Vita Corporation
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Danaher Corporation (Cepheid)
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Seegene Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Becton, Dickinson and Company
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. TruScreen
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Abbott Laboratories
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Hologic Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Qiagen NV
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. F. Hoffmann-La Roche AG
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. OncoHealth Corporation
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Takara Bio Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Promega Corporation
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Quest Diagnostics
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Femasys Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Mylab Discovery Solutions Pvt Ltd.
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy
  • 7.16. Thermo Fisher Scientific Inc
    • 7.16.1. Company Overview
    • 7.16.2. Company Snapshot
    • 7.16.3. Financial Overview
    • 7.16.4. Product Listing
    • 7.16.5. Entropy
  • 7.17. bioMerieux SA
    • 7.17.1. Company Overview
    • 7.17.2. Company Snapshot
    • 7.17.3. Financial Overview
    • 7.17.4. Product Listing
    • 7.17.5. Entropy
  • 7.18. Nurx
    • 7.18.1. Company Overview
    • 7.18.2. Company Snapshot
    • 7.18.3. Financial Overview
    • 7.18.4. Product Listing
    • 7.18.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us